Click for best price
Alpha1 Antitrypsin Deficiency Augmentation Therapy Market Size, Share 2023
Alpha-1 antitrypsin deficiency (AATD) is an inherited condition characterized as a low or unpredictable level of alpha-1 protein, generated by liver. The disease most commonly affects lungs and liver and is often undiagnosed. Augmentation therapy is the most specific therapy for the treatment of AATD, and includes various preparations derived from pooled human plasma.
This report aims to provide a comprehensive presentation of the global market for Alpha-1 Antitrypsin Deficiency Augmentation Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Alpha-1 Antitrypsin Deficiency Augmentation Therapy. This report contains market size and forecasts of Alpha-1 Antitrypsin Deficiency Augmentation Therapy in global, including the following market information:
Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Revenue, 2018-2023, 2024-2030, ($ millions)
Global top five companies in 2022 (%)
The global Alpha-1 Antitrypsin Deficiency Augmentation Therapy market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Glassia Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Alpha-1 Antitrypsin Deficiency Augmentation Therapy include Grifols, CSL, Baxter, Kamada, Takeda and Abeona, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Alpha-1 Antitrypsin Deficiency Augmentation Therapy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, by Type, 2018-2023, 2024-2030 ($ millions)
Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Segment Percentages, by Type, 2022 (%)
Glassia
Aralast NP
Prolastin C
Others
Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, by Application, 2018-2023, 2024-2030 ($ millions)
Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Segment Percentages, by Application, 2022 (%)
Hospitals
Specialty Clinics
Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions)
Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Alpha-1 Antitrypsin Deficiency Augmentation Therapy revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Alpha-1 Antitrypsin Deficiency Augmentation Therapy revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Grifols
CSL
Baxter
Kamada
Takeda
Abeona
Outline of Major Chapters:
Chapter 1: Introduces the definition of Alpha-1 Antitrypsin Deficiency Augmentation Therapy, market overview.
Chapter 2: Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy market size in revenue.
Chapter 3: Detailed analysis of Alpha-1 Antitrypsin Deficiency Augmentation Therapy company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Alpha-1 Antitrypsin Deficiency Augmentation Therapy in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
Report Attributes |
Report Details |
Report Title |
Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Global Outlook and Forecast 2023-2030 |
Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
Base Year |
2022 |
Forecast Year |
2030 |
Number of Pages |
61 Pages |
Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Overall Market Size
2.1 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size: 2022 VS 2030
2.2 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size, Prospects & Forecasts: 2018-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Alpha-1 Antitrypsin Deficiency Augmentation Therapy Players in Global Market
3.2 Top Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Companies Ranked by Revenue
3.3 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Companies
3.4 Top 3 and Top 5 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Companies in Global Market, by Revenue in 2022
3.5 Global Companies Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product Type
3.6 Tier 1, Tier 2 and Tier 3 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Players in Global Market
3.6.1 List of Global Tier 1 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Companies
3.6.2 List of Global Tier 2 and Tier 3 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Markets, 2022 & 2030
4.1.2 Glassia
4.1.3 Aralast NP
4.1.4 Prolastin C
4.1.5 Others
4.2 By Type - Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue & Forecasts
4.2.1 By Type - Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, 2018-2023
4.2.2 By Type - Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, 2024-2030
4.2.3 By Type - Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share, 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size, 2022 & 2030
5.1.2 Hospitals
5.1.3 Specialty Clinics
5.2 By Application - Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue & Forecasts
5.2.1 By Application - Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, 2018-2023
5.2.2 By Application - Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, 2024-2030
5.2.3 By Application - Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share, 2018-2030
6 Sights by Region
6.1 By Region - Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size, 2022 & 2030
6.2 By Region - Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue & Forecasts
6.2.1 By Region - Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, 2018-2023
6.2.2 By Region - Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, 2024-2030
6.2.3 By Region - Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share, 2018-2030
6.3 North America
6.3.1 By Country - North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, 2018-2030
6.3.2 US Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size, 2018-2030
6.3.3 Canada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size, 2018-2030
6.3.4 Mexico Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size, 2018-2030
6.4 Europe
6.4.1 By Country - Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, 2018-2030
6.4.2 Germany Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size, 2018-2030
6.4.3 France Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size, 2018-2030
6.4.4 U.K. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size, 2018-2030
6.4.5 Italy Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size, 2018-2030
6.4.6 Russia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size, 2018-2030
6.4.7 Nordic Countries Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size, 2018-2030
6.4.8 Benelux Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size, 2018-2030
6.5 Asia
6.5.1 By Region - Asia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, 2018-2030
6.5.2 China Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size, 2018-2030
6.5.3 Japan Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size, 2018-2030
6.5.4 South Korea Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size, 2018-2030
6.5.5 Southeast Asia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size, 2018-2030
6.5.6 India Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size, 2018-2030
6.6 South America
6.6.1 By Country - South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, 2018-2030
6.6.2 Brazil Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size, 2018-2030
6.6.3 Argentina Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size, 2018-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, 2018-2030
6.7.2 Turkey Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size, 2018-2030
6.7.3 Israel Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size, 2018-2030
6.7.4 Saudi Arabia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size, 2018-2030
6.7.5 UAE Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size, 2018-2030
7 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Companies Profiles
7.1 Grifols
7.1.1 Grifols Company Summary
7.1.2 Grifols Business Overview
7.1.3 Grifols Alpha-1 Antitrypsin Deficiency Augmentation Therapy Major Product Offerings
7.1.4 Grifols Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue in Global Market (2018-2023)
7.1.5 Grifols Key News & Latest Developments
7.2 CSL
7.2.1 CSL Company Summary
7.2.2 CSL Business Overview
7.2.3 CSL Alpha-1 Antitrypsin Deficiency Augmentation Therapy Major Product Offerings
7.2.4 CSL Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue in Global Market (2018-2023)
7.2.5 CSL Key News & Latest Developments
7.3 Baxter
7.3.1 Baxter Company Summary
7.3.2 Baxter Business Overview
7.3.3 Baxter Alpha-1 Antitrypsin Deficiency Augmentation Therapy Major Product Offerings
7.3.4 Baxter Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue in Global Market (2018-2023)
7.3.5 Baxter Key News & Latest Developments
7.4 Kamada
7.4.1 Kamada Company Summary
7.4.2 Kamada Business Overview
7.4.3 Kamada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Major Product Offerings
7.4.4 Kamada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue in Global Market (2018-2023)
7.4.5 Kamada Key News & Latest Developments
7.5 Takeda
7.5.1 Takeda Company Summary
7.5.2 Takeda Business Overview
7.5.3 Takeda Alpha-1 Antitrypsin Deficiency Augmentation Therapy Major Product Offerings
7.5.4 Takeda Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue in Global Market (2018-2023)
7.5.5 Takeda Key News & Latest Developments
7.6 Abeona
7.6.1 Abeona Company Summary
7.6.2 Abeona Business Overview
7.6.3 Abeona Alpha-1 Antitrypsin Deficiency Augmentation Therapy Major Product Offerings
7.6.4 Abeona Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue in Global Market (2018-2023)
7.6.5 Abeona Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Opportunities & Trends in Global Market
Table 2. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Drivers in Global Market
Table 3. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Restraints in Global Market
Table 4. Key Players of Alpha-1 Antitrypsin Deficiency Augmentation Therapy in Global Market
Table 5. Top Alpha-1 Antitrypsin Deficiency Augmentation Therapy Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Share by Companies, 2018-2023
Table 8. Global Companies Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product Type
Table 9. List of Global Tier 1 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2022 & 2030
Table 12. By Type - Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue in Global (US$, Mn), 2024-2030
Table 14. By Application ? Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2022 & 2030
Table 15. By Application - Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue in Global (US$, Mn), 2024-2030
Table 17. By Region ? Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2022 & 2030
Table 18. By Region - Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (US$, Mn), 2024-2030
Table 20. By Country - North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2024-2030
Table 22. By Country - Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2024-2030
Table 24. By Region - Asia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2024-2030
Table 26. By Country - South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2024-2030
Table 28. By Country - Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2024-2030
Table 30. Grifols Company Summary
Table 31. Grifols Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product Offerings
Table 32. Grifols Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (US$, Mn) & (2018-2023)
Table 33. Grifols Key News & Latest Developments
Table 34. CSL Company Summary
Table 35. CSL Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product Offerings
Table 36. CSL Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (US$, Mn) & (2018-2023)
Table 37. CSL Key News & Latest Developments
Table 38. Baxter Company Summary
Table 39. Baxter Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product Offerings
Table 40. Baxter Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (US$, Mn) & (2018-2023)
Table 41. Baxter Key News & Latest Developments
Table 42. Kamada Company Summary
Table 43. Kamada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product Offerings
Table 44. Kamada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (US$, Mn) & (2018-2023)
Table 45. Kamada Key News & Latest Developments
Table 46. Takeda Company Summary
Table 47. Takeda Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product Offerings
Table 48. Takeda Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (US$, Mn) & (2018-2023)
Table 49. Takeda Key News & Latest Developments
Table 50. Abeona Company Summary
Table 51. Abeona Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product Offerings
Table 52. Abeona Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (US$, Mn) & (2018-2023)
Table 53. Abeona Key News & Latest Developments
List of Figures
Figure 1. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Segment by Type in 2022
Figure 2. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Segment by Application in 2022
Figure 3. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size: 2022 VS 2030 (US$, Mn)
Figure 6. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, 2018-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue in 2022
Figure 8. By Type - Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share, 2018-2030
Figure 9. By Application - Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share, 2018-2030
Figure 10. By Type - Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2022 & 2030
Figure 11. By Type - Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share, 2018-2030
Figure 12. By Application - Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2022 & 2030
Figure 13. By Application - Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share, 2018-2030
Figure 14. By Region - Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share, 2018-2030
Figure 15. By Country - North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share, 2018-2030
Figure 16. US Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2018-2030
Figure 17. Canada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2018-2030
Figure 18. Mexico Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2018-2030
Figure 19. By Country - Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share, 2018-2030
Figure 20. Germany Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2018-2030
Figure 21. France Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2018-2030
Figure 22. U.K. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2018-2030
Figure 23. Italy Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2018-2030
Figure 24. Russia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2018-2030
Figure 25. Nordic Countries Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2018-2030
Figure 26. Benelux Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2018-2030
Figure 27. By Region - Asia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share, 2018-2030
Figure 28. China Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2018-2030
Figure 29. Japan Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2018-2030
Figure 30. South Korea Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2018-2030
Figure 31. Southeast Asia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2018-2030
Figure 32. India Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2018-2030
Figure 33. By Country - South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share, 2018-2030
Figure 34. Brazil Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2018-2030
Figure 35. Argentina Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2018-2030
Figure 36. By Country - Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share, 2018-2030
Figure 37. Turkey Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2018-2030
Figure 38. Israel Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2018-2030
Figure 39. Saudi Arabia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2018-2030
Figure 40. UAE Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue, (US$, Mn), 2018-2030
Figure 41. Grifols Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. CSL Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Baxter Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Kamada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Takeda Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Abeona Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)